3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Hypothyroidism
1
Hepatic Encephalopathy
1
Goiter
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
Glucose
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts